

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells

Mikel Gurrea-Rubio

University of Michigan

Qi Wu

University of Michigan

M. Asif Amin

University of Michigan

Pei-Suen Tsou

University of Michigan

Phillip L. Campbell

University of Michigan

Camila E. Amarista

University of Michigan

Yuzo Ikari

University of Michigan

William D. Brodie

University of Michigan

Megan N. Mattichak

University of Michigan

Sei Muraoka

University of Michigan

Peggy M. Randon

University of Michigan

Matthew E. Lind

University of Michigan

Jeffrey H. Ruth

University of Michigan

Yang Mao-Draayer

University of Michigan

Shengli Ding

Xilis, Inc

Xiling Shen

Xilis, Inc

Laura A. Cooney

University of Michigan

Feng Lin

Lerner Research Institute

David A. Fox (✉ dfox@med.umich.edu)

University of Michigan

Research Article

Keywords: CD6, immunotherapy, NK, cytotoxic lymphocyte

Posted Date: October 9th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3405677/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: Competing interest reported. Competing Interests: Drs. Fox and Lin are co-holders of US patents related to the use of therapeutic agents that interrupt the interactions between CD6 and CD6 ligands in the treatment of cancer and autoimmunity. They also hold equity in Abcon, a company created to test such agents.

Version of Record: A version of this preprint was published at Cancer Immunology, Immunotherapy on January 27th, 2024. See the published version at <https://doi.org/10.1007/s00262-023-03578-1>.

Abstract

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with their use. Therefore, safer approaches are needed. CD6, expressed by T-lymphocytes and human NK cells, engages in cell-cell interactions by binding to its ligands CD166 (ALCAM) and CD318 (CDCP1). *CD6* is a target protein for regulating immune responses and is required for the development of several mouse models of autoimmunity. Interestingly, CD6 is exclusively expressed on immune cells while CD318 is strongly expressed on most cancers. Here we demonstrate that disrupting the CD6-CD318 axis with UMCD6, an anti-CD6 monoclonal antibody, prolongs survival of mice in xenograft models of human breast and prostate cancer, treated with infusions of human lymphocytes. Analysis of tumor-infiltrating immune cells showed that augmentation of lymphocyte cytotoxicity by UMCD6 is due to effects of this antibody on NK, NKT and CD8+ T cells. Tumor-infiltrating cytotoxic lymphocytes were found in higher proportions and were activated in UMCD6-treated mice compared to controls. Similar changes in gene expression were observed by RNA-seq analysis of NK cells treated with UMCD6. Particularly, UMCD6 up-regulated the NKG2D-DAP10 complex and activated PI3K. Thus, the CD6-CD318 axis can regulate the activation state of cytotoxic lymphocytes and their positioning within the tumor microenvironment.

INTRODUCTION

Inhibition of immune checkpoints using monoclonal antibodies (mAbs) against CTLA-4, PD-1 and PD-L1 has revolutionized the outlook for some cancer patients. Despite their success in the clinic, the use of these immune checkpoint inhibitors is hindered by the appearance of severe immune-related adverse events, restricting the number of patients who achieve durable responses.

Our previous work showed that CD6, a cell surface protein expressed by T lymphocytes and human NK cells^{1,2}, is essential in mouse models of multiple sclerosis³, rheumatoid arthritis⁴, and uveitis⁵. In both CD6^{-/-} mice and CD6-humanized mice treated with UMCD6, an anti-human CD6 mAb, striking reductions in clinical signs of disease, pathogenic Th1/Th17 responses and inflammatory cell infiltration into the target organs were observed. Soon after discovering CD318 (CDCP1) as the second ligand of CD6⁶, we demonstrated that interrupting the CD6-CD318 axis with a single dose of UMCD6 enhances the capacity of human PBMC (peripheral blood mononuclear cells) to kill CD318 + breast, prostate and lung cancer cells *in vitro*, and breast cancer cells *in vivo*⁷. CD318 has been extensively studied in cancer because of its correlation with higher occurrence of metastases⁸ and poor prognosis in most cancers⁸, due to its role in metastasis formation through interaction with integrins and anti-apoptotic signaling *via* Akt⁹.

In light of these observations, we have evaluated the longer-term effects of interrupting the CD6-CD318 axis with UMCD6 on treatment of breast and prostate cancers *in vivo* and probed the mechanisms by which UMCD6 increased lymphocyte-mediated cytotoxicity against cancer cells. Weekly injections of UMCD6 increased survival and augmented killing (by PBMC or isolated NK cells) of breast and prostate

cancer cells xeno-transplanted into immunodeficient mice. Next, we demonstrated that tumor-infiltrating lymphocytes (TILs) from UMCD6-treated mice contain higher proportions of cytotoxic lymphocytes and have higher cytotoxic activity capacity. We found an increased frequency of CD56^{dim}/CD16^{bright} NK cells, NKT cells and CD8 + T cells, and higher perforin production in TILs from UMCD6-treated xenografted mice. These findings correlate with RNA-seq data from NK-92 cells that shows widespread changes in gene expression of several activating receptors (NKG2D-DAP10 and 2B4) and granzyme genes by UMCD6. Altogether, these results provide mechanistic support for anti-CD6 therapy as a promising mAb for cancer immunotherapy. Moreover, because UMCD6 can suppress many autoimmune syndromes by its direct effects on CD4 + T cells^{3-5,10}, the use of this antibody to treat human cancer could avoid the troubling autoimmune complications frequently seen with current checkpoint inhibitors.

MATERIALS AND METHODS

Cell lines and cell culture. MDA-MB-231 (HTB-26™), MDA-MB-468 (HTB-132™), PC-3 (CRL-1435™) and NK-92 cells (CRL-2427™) were purchased from the American Type Culture Collection (ATCC) and expanded according to AATC guidelines.

Xenografts. All animal experiments were conducted in compliance with the Animal Care and Use Committee at the University of Michigan. Severe combined immunodeficient (SCID) beige mice (Charles River) were anesthetized intraperitoneally with ketamine (80 mg/kg) and xylazine (5 mg/kg) and injected subcutaneously with either 2×10⁶ luciferase-infected MDA-MB-231 cells or PC-3 cells into the right flank. When tumors reached volumes of 1 cm, mice were infused with 1.5×10⁷ PBMC or 2×10⁶ NK cells via the tail vein. Mice received intraperitoneal injections of UMCD6, anti-PD-1 or IgG control antibodies (100 µg/mouse) every 14 days. Tumor growth was monitored by bioluminescence imaging as described before⁷.

Generation of MicroOrganoSpheres (MOS). Lung tumor tissue samples were processed, and MOS were generated as described previously^{11,12}. MOS were cultured in medium containing DMEM/F12 (HyClone), HEPES (Gibco) and Glutamax (Gibco Life Technologies) and dosed on day 2 with anti-PD1, UMCD6 and controls for 4 days. Annexin V green dye was used to indicate cell death and longitudinal images were taken in the Incucyte®.

Isolation of human peripheral mononuclear cells (PBMC) and NK cells. PBMCs were isolated by density gradient centrifugation using Ficoll-Paque (GE Healthcare) from healthy volunteers. NK cells were isolated using the EasySep® Human NK Cell Isolation Kit (STEMCELL Technologies) per manufacturer's instructions.

RNAseq analysis. Bulk RNA-seq was performed by Novogene. A total of 6 samples were used for these experiments. To prepare these samples, total RNA from NK-92 cells treated with 10 µg/ml of UMCD6 or IgG for 6 hours was extracted using RNAeasy MiniPrep Kit (Qiagen). Samples were then sequenced on an Illumina HiSeq platform and 125 bp/150 bp paired-end reads were generated. Index of the reference

genome was built using Bowtie v2.2.3 and paired-end clean reads were aligned to the reference genome using TopHat v2.0.12. Differential gene expression analysis was performed using DESeq2. P values were adjusted using the Benjamini & Hochberg method. Corrected P-value of 0.05 and log₂ (Fold-change) of 1 were set as the threshold for significantly differential expression.

RT-PCR analysis. NK-92 cells were treated with 10 µg/ml of UMCD6 and harvested at 6 hours. RNA was extracted using Direct-zol RNA MiniPrep (Zymo Research). mRNA expression was measured using SYBR Green PCR Master Mix Reagent (Thermo Fisher Scientific) and the following primers: NKG2D F: 5'-TTCAACACGATGGCAAAGC-3', NKG2D R: 5'-CTACAGCGATGAAGCAGCAGA-3', HCST F: 5'-TCTGGGTCACATCCTCTTCCT-3' and HCST R: 5'-AAGTGCCAGGGTAAAAGGCAG-3'). Real abundance was calculated using the $\Delta\Delta$ CT method on a ViiA V.7 Real-Time PCR System (Applied Biosystems).

Western blotting. NK-92 cells were treated with UMCD6 or an IgG control antibody at 10 µg/ml and cell lysates were collected after 72 hours. To measure changes in PI3K and mTOR expression, HRP-conjugated antibodies to PI3K (Cell Signaling, Cat#428T), and mTOR (Cell Signaling, Cat#2972) were used at 1:1000 in 5% milk. β -actin (Cell Signaling, Cat#13E5) was used control for loading. Bands were imaged on an Amersham Imager 600RGB (GE Healthcare).

Antibodies. Pembrolizumab and nivolumab (anti-PD-1) were obtained from Merck and Bristol-Myers Squibb. The following antibodies were used for flow cytometry analyses: FITC anti-human CD4 (BioLegend Cat#391503), PE anti-human CD45 (Biolegend, clone HI30), APC anti-human CD56 (Biolegend, clone 5.1H11), APC/Cyanine7 anti-human CD8a (Biolegend, San Diego, CA, USA, clone RPA-T8), PE/Cyanine7 anti-human CD3 (Biolegend, clone HIT3a), PerCP/Cyanine5.5 anti-human CD314 (NKG2D) (Biolegend, clone 1D11), FITC anti-human CD6 (Biolegend, clone BL-CD6), APC anti-human CD16 (Biolegend, clone 3G8), Pacific Blue anti-human/mouse Ki67 (Biolegend, clone 16A8), FITC anti-human/mouse Granzyme B (Biolegend, clone GB11) and APC anti-human Perforin (Biolegend, clone B-D48).

Immunohistochemistry. Xenograft tumors derived from breast cancer MDA-MB-231 cells were embedded in optimal cutting temperature compound (Sakura Finetek) for cryosectioning at 8 µm. Antibodies against CD56 (Biolegend, clone 5.1H11) were incubated at 1:100 dilutions overnight. The following day, slides were incubated with goat anti-mouse IgG-Cy3 antibodies (Jackson ImmunoResearch) for 1 hour at room temperature. Fluorescence images were taken using an Olympus BX51 microscope (Olympus America Inc.).

Statistical Analysis. The statistical analysis for all the experiments was performed using Graph Pad Prism software (GraphPad Prism). Bioluminescence, RT-PCR and western blot data are shown as mean \pm standard error of the mean and statistical significance between two groups (for normally distributed data) was determined by the unpaired Student's t test. ANOVA was used for not normally distributed data.

RESULTS

UMCD6 augments killing by human PBMC of breast cancer cells xenotransplanted into immunodeficient mice and increases survival of treated mice. To investigate the long-term efficacy of UMCD6, we generated a xenograft mouse model of breast cancer by subcutaneous injections of 2×10^6 luciferase-labeled MDA-MB-231 cells into SCID/beige mice. When tumors reached 1 cm in diameter, mice were infused with 10^7 human PBMC and treated, beginning the day after the PBMC infusion, with 100 μ g of UMCD6 or control IgG antibody once a week. Tumor volume, measured by bioluminescence signal (Fig. 1A), was significantly reduced by UMCD6 from day 7 and this effect was maintained until at least day 28 ($*p < 0.05$) (Figs. 1B and 1C). Exit from the study was defined for each mouse as the day on which tumors reached ≥ 2 cm in diameter and/or ulceration covered $\geq 50\%$ of the tumor region. A robust increase in survival can be seen in the UMCD6 treated mice (100% alive, $n = 8$) compared to IgG-treated (25% alive, $n = 8$) and control mice (25% alive; $n = 4$) at day 38 (Fig. 1D). In a parallel experiment in which the main goal was to compare the short-term efficacy of UMCD6 versus anti-PD-1 therapy *in vivo*, we found that the effect of UMCD6 might be more sustained in the killing of MDA-MB-231-derived xenograft tumors by PBMC than the effect of anti-PD-1. As seen in Fig. 2A, both UMCD6 and pembrolizumab enhanced tumor killing by PBMC at day 8 compared to IgG control ($*p < 0.05$), but only UMCD6 showed statistical significance at day 11 ($*p < 0.05$) (Fig. 2B). Consistent with these findings, CD56⁺ cells were found in higher proportions in histological sections from tumors from UMCD6-treated MDA-MB-231 xenografts in comparison with tumor sections from the IgG-treated group ($*p < 0.05$). The increase in the number of tumor-infiltrating NK cells with anti-PD-1 therapy was not significant when compared to IgG (Figs. 2C and 2D). To demonstrate that the mechanism of action of UMCD6 differs from conventional immunotherapies, we isolated and characterized a portion of the tumor infiltrating lymphocytes (TILs) by flow cytometry. In agreement with our immunofluorescence results, we found an increase in the percentage of tumor-infiltrating NK cells in UMCD6-treated mice (5.8%) compared with IgG (2.01%; $p = 0.06$) and anti-PD-1 (1.92%; $p = 0.06$) (Fig. 2E). Moreover, tumor-infiltrating NK and NKT cells from UMCD6-treated xenografts expressed higher levels of the activating receptor NKG2D ($*p < 0.05$) than those found in IgG and anti-PD-1 treated mice (Figs. 2E and 2F). The trend seen in the up-regulation of perforin expression and the statistically significant up-regulation of the activating receptor NKG2D in both NK cells and NK-T cells upon treatment with UMCD6, is consistent with our previous findings *in vitro*⁷ and indicates UMCD6 activation of NK cells *in vivo*.

UMCD6 increases cytotoxicity of tumor-infiltrating lymphocytes (TILs). To study the phenotypic changes that occur on human lymphocytes upon treatment with UMCD6 *in vivo*, we collected and characterized TILs from our MDA-MB-231 xenografts during peak killing 4 days post-treatment with anti-CD6. First, we confirmed that CD6 expression was robustly down-regulated on virtually all TILs (**supplementary Fig. 3**), demonstrating that treatment with UMCD6 *in vivo* had effects on CD6 surface expression identical to what had previously been observed *in vitro*⁷. Importantly, TILs from UMCD6-treated mice showed an increased frequency of NK cells, specifically CD56^{dim} cells ($*p < 0.05$), CD8⁺ T cells and NKT cells compared with IgG-treated TILs. On average, TILs from UMCD6-treated mice comprised a mixture of NK cells (3.14% \pm 0.6), NKT cells (18.65% \pm 2.25), CD8⁺ T cells (16.18% \pm 4.28) and CD4⁺ T cells (57.16% \pm 5.79), whereas TILs from IgG-treated mice showed lower proportions of NK cells (2.33% \pm 0.37), NKT cells

(14.72% ± 2.74) and CD8 + T cells (13.90% ± 2.33), but higher proportions of CD4 + T cells (62.15% ± 6.28) (Figs. 3A and 3B). Perforin production was up-regulated by NK cells, NKT cells ($*p < 0.05$), CD8 + T cells and a small portion of CD4 + T cells ($*p < 0.05$) (Figs. 3C and 3D).

UMCD6 modulates the expression of key receptors and granzyme genes in NK cells. We performed RNA-seq using the NK cell line NK-92 after culture with UMCD6 and compared the transcriptomic profile to that of IgG-treated NK-92 cells. Despite the highly activated status of NK-92 cells¹³, our results showed widespread changes in gene expression induced by UMCD6 in a 6-hour culture. 180 genes were altered significantly, with 94 of them being up-regulated and 86 down-regulated (**Fig. 4A**). These genes include several activating receptors and others that fall into categories such as granzyme production, activation of chemokines and genes whose protein products are viewed as important in the tumor microenvironment. Among the most important up-regulated genes, we found the potent activating receptor *KLRK1* [NKG2D] and its transmembrane signaling adaptor *HCST* [DAP10] ($*p < 0.05$), a receptor complex essential for optimal NK cell and CD8 + T cell activation¹⁴. *CD244* [2B4], another NK activating receptor, showed a trend towards up-regulation by UMCD6 ($p < 0.1$). Importantly, several granzyme-related genes were up-regulated. These include granzyme-M ($*p < 0.05$) and granzyme-B ($*p < 0.05$). Notably, *CCL5* (chemokine ligand 5), whose expression is associated with recruitment of NK cells and dendritic cells in the tumor microenvironment^{15,16}, was robustly up-regulated upon treatment with UMCD6 ($**p < 0.01$). Among the most significant down-regulated genes, we found *TSC1* (TSC Complex Subunit 1), a negative regulator of NK proliferation¹⁷, and *MALAT1* (Metastasis Associated Lung Adenocarcinoma Transcript 1), a negative regulator of Th1 and Th2 differentiation ($**p < 0.01$). Next, we validated the RNA-seq results performing qRT-PCR analyses and confirmed up-regulation of the NKG2D-DAP10 receptor complex on NK cells upon activation with UMCD6 (**Fig. 4B**). Recent literature has demonstrated that NKG2D-DAP10 ligation triggers cytotoxicity in human NK cells by activation of the phosphoinositide 3-kinase (PI3K) pathway^{14,18,19}. Our data demonstrates that UMCD6 up-regulates NKG2D/DAP10 expression and activates the PI3K and mTOR pathways on human NK cells, suggesting that one mechanism of activation of NK cells by UMCD6 could be by activation of the NKG2D-DAP10 complex and its downstream pathways (**Figs. 4C and 4D**).

UMCD6 enhances NK killing of human breast cancer cells in vivo. Because UMCD6 directly activates NK cells without the need for CD4 + T cells *in vitro*⁷, we tested the efficacy of UMCD6 to enhance killing of xenografted breast cancer cells by using isolated human NK cells *in vivo*. MDA-MB-231 xenografts were infused with 1×10^6 human NK cells once, followed by weekly injections of UMCD6 or IgG until mice required euthanasia. Bioluminescence imaging of MDA-MB-231 tumor-bearing mice (Fig. 5) revealed a decrease in tumor growth in mice receiving NK cells and UMCD6 at day 3 and 8 compared to IgG control. Moreover, survival was significantly enhanced in the UMCD6 group compared either of the IgG and control groups (UMCD6 vs. IgG, $*p = 0.0246$; UMCD6 vs. untreated, $*p = 0.0389$). We conclude that NK cells are directly stimulated by UMCD6, *in vitro* and *in vivo*, to kill cancer cells with significantly enhanced efficiency.

UMCD6 enhances killing of patient-derived lung cancer micro-organospheres

(MOS). To test whether UMCD6 could enhance resident immune cells killing of patient-derived lung tumorspheres, MOS technology was used to produce patient-derived micro-tumor organoids from three different CD318 + lung cancer patients. Our experiments demonstrated that UMCD6 induces apoptosis of lung tumor cells, at least as efficiently as nivolumab (PD-1 inhibitor) in 2 out of 3 patients (**Figs. 6A, 6B and 6C**). The non-responder sample (501551) had the lowest lymphocyte to epithelial cell ratio (T cells/EpCAM), which might explain why neither UMCD6 nor anti-PD1 induced lung cancer death (**Fig. 6D**).

UMCD6 enhances prostate cancer killing by PBMC. We previously demonstrated that in *in vitro* co-culture models between prostate tumor cells and PBMC, UMCD6 augmented killing of LNCaP and PC3 prostate cancer cell lines through direct activation of NK and CD8 + T cells⁷. We now demonstrate that *in vivo*, UMCD6 increases survival and augments killing by human PBMC of PC3 cells xeno-transplanted into immunodeficient mice. The effect of UMCD6 on inhibiting tumor growth was measured by bioluminescence imaging and can be seen 14 days after UMCD6 administration. This effect was prolonged even though no additional infusions of lymphocytes were provided. Survival was significantly improved in the UMCD6 group compared to the pooled control group (** $p < 0.01$) (**supplementary Fig. 1**).

Pharmacodynamics of UMCD6. To gather information about the therapeutic potential of UMCD6, SCID/beige mice were infused with 1×10^7 human lymphocytes and treated with one dose of UMCD6 or IgG control antibody (100 μ g and 400 μ g/mouse). Lymphocytes were recovered at day from whole blood and expression/re-expression of CD6 on lymphocytes subsets was assessed by flow cytometry. As shown in (**supplementary Fig. 2**), CD6 expression was reduced by at least 75% by day 4 in all cell subsets, and such effect was maintained until at least day 7. Complete re-expression of CD6 only occurred by day 14 on CD4 + NKT cells, but not on CD4 + or NK cells. An increase in CD6 expression on CD8 + NKT cells upon treatment with IgG suggests the existence of yet unknown mechanism that uniquely regulates CD6 expression by this subpopulation of lymphocytes.

DISCUSSION

The data presented in this report provide mechanistic insights regarding the effects of UMCD6 on the enhancement of NK cell and T cell responses against CD318 + cancers *in vivo*. We demonstrated that UMCD6 increases survival and augments killing by both PBMC and isolated NK cells of both triple-negative breast cancer and prostate cancer cells xenografted into immunodeficient mice. Of particular interest from both cancer immunotherapy and autoimmunity perspectives is the demonstrated ability of UMCD6 to prevent or reverse multiple models of human autoimmune disease¹⁰, which provides an important advantage compared to current checkpoint inhibitors.

NK cells are increasingly becoming important components of therapeutic strategies for cancer because of their ability to kill tumor cells in a non-MHC-restricted manner. Our analysis of TILs confirmed that

augmentation of lymphocyte cytotoxicity by UMCD6 is due to effects of this antibody primarily on NK cells, but also NKT cells, CD8 + T cells and even a small fraction of CD4 + T cells. Moreover, *in vivo* experiments using a single infusion of a small number of purified human NK cells, also increased survival of MDA-MB-231 xenografts.

Current understanding of the function of cytotoxic lymphocytes encompasses roles for many stimulatory and inhibitory receptors. In this report, we have demonstrated that augmentation of lymphocyte cytotoxic function by UMCD6 occurs when CD6 is internalized and no longer on the cell surface of NK cells. This functional change increases the expression of at least two activating receptors (NKG2D and 2B4) and their downstream signaling pathways (PI3K and mTOR), as well as various granzymes.

Natural killer-T cells (NKT cells) are a unique subset of CD1d-restricted T cells that share characteristics of both the innate and adaptive immune systems. As in NK cells, NKT cells rely on the balance between stimulatory and inhibitory signals via modulating the expression of several activating and inhibitory receptors²⁰. In addition, NKT cells express CD16 which is known to trigger antibody-dependent cellular cytotoxicity by NK cells, making them an ideal target for the development of cancer immunotherapy. Our recent data demonstrate the importance of NKT cells in mediating killing of cancer cells *in vivo* upon activation with UMCD6, likely due to increase in the expression of NK-like activating receptors. Importantly, antibody-dependent cellular cytotoxicity is not an explanation for the effects of UMCD6, since this antibody does not bind to the cancer cells. Instead, binding and internalization of UMCD6 and cell surface CD6 directly alters the program of gene expression in lymphocytes, while controlling the effects of signals from CD6 ligands on cancer cells.

The ability of UMCD6 to enhance killing of patient-derived cancers in MOS demonstrates efficacy of UMCD6 in fully autologous human cancers *ex vivo*. This technology provides an excellent setting to understand and predict patient-specific responses because it uses organoids that retain the intratumoral heterogeneity and tumor clonal hierarchy from the patient's own tumor. Our studies demonstrating that UCMD6 induces apoptosis of lung cancer cells in MOS, at least as efficiently as nivolumab, coupled with our previous data showing the ability of UMCD6 to suppress and control autoimmune diseases, fortify the pre-clinical rationale for the study of anti-CD6 as an effective and safer approach for cancer immunotherapy.

Declarations

Acknowledgements: this study was supported by funds from the NIH Autoimmunity Center of Excellence and Training Grant T32AR007080, with additional funds from the Michigan Translational Research And Commercialization program and the Frederick Huetwell and William Robinson Professorship in Rheumatology at the University of Michigan.

Ethics approval and consent to participate: This study was approved by the University of Michigan Institutional Review Board. Written informed consent was received from participants prior to inclusion in

the study.

Competing Interests: Drs. Fox and Lin hold equity in Abcon, a company created to test the use of therapeutic agents that interrupt the interactions between CD6 and CD6 ligands.

References

1. Martinez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. *Pharmacol Rev.* 2011; 63(4):967–1000. PMID: 21880988.
2. Braun M, Muller B, ter Meer D, Raffegerst S, Simm B, Wilde S, Spranger S, Ellwart J, Mosetter B, Umansky L, Lerchl T, Schendel DJ, Falk CS. The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion. *J Innate Immun.* 2011; 3(4):420–434. PMID: 21178331.
3. Li Y, Singer NG, Whitbred J, Bowen MA, Fox DA, Lin F. CD6 as a potential target for treating multiple sclerosis. *Proc Natl Acad Sci U S A.* 2017; 114(10):2687–2692. PMID: 28209777. PMCID: PMC5347585.
4. Li Y, Ruth JH, Rasmussen SM, Athukorala KS, Weber DP, Amin MA, Campbell PL, Singer NG, Fox DA, Lin F. Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6. *Arthritis Rheumatol.* 2020; 72(9):1505–1513. PMID: 32307907. PMCID: PMC7745675.
5. Zhang L, Li Y, Qiu W, Bell BA, Dvorina N, Baldwin WM, 3rd, Singer N, Kern T, Caspi RR, Fox DA, Lin F. Targeting CD6 for the treatment of experimental autoimmune uveitis. *J Autoimmun.* 2018; 90:84–93. PMID: 29472120. PMCID: PMC5949263.
6. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. *Proc Natl Acad Sci U S A.* 2017; 114(33):E6912-E6921. PMID: 28760953. PMCID: PMC5565428.
7. Ruth JH, Gurrea-Rubio M, Athukorala KS, Rasmussen SM, Weber DP, Randon PM, Gedert RJ, Lind ME, Amin MA, Campbell PL, Tsou PS, Mao-Draayer Y, Wu Q, Lanigan TM, Keshamouni VG, Singer NG, Lin F, Fox DA. CD6 is a target for cancer immunotherapy. *JCI Insight.* 2021; 6(5): PMID: 33497367. PMCID: PMC8021120.
8. Khan T, Kryza T, Lyons NJ, He Y, Hooper JD. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. *Cancer Res.* 2021; 81(9):2259–2269. PMID: 33509939.
9. Uekita T, Sakai R. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. *Cancer Sci.* 2011; 102(11):1943–1948. PMID: 21812858.
10. Gurrea-Rubio M, Fox DA. The dual role of CD6 as a therapeutic target in cancer and autoimmune disease. *Front Med (Lausanne).* 2022; 9:1026521. PMID: 36275816. PMCID: PMC9579686.
11. Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, Giroux N, Rivera GO, Dohlman A, Bose S, Rotstein T, Spiller K, Yeung A, Sun Z, Jiang C, Xi R, Wilkin B, Randon PM, Williamson I, Nelson DA, Delubac D, Oh S, Rupprecht G, Isaacs J, Jia J, Chen C, Shen JP, Kopetz S, McCall S, Smith A, Gjorevski

- N, Walz AC, Antonia S, Marrer-Berger E, Clevers H, Hsu D, Shen X. Patient-derived micro-organospheres enable clinical precision oncology. *Cell Stem Cell*. 2022; 29(6):905–917 e906. PMID: 35508177. PMCID: PMC9177814.
12. Wang Z, Boretto M, Millen R, Natesh N, Reckzeh ES, Hsu C, Negrete M, Yao H, Quayle W, Heaton BE, Harding AT, Bose S, Driehuis E, Beumer J, Rivera GO, van Ineveld RL, Gex D, DeVilla J, Wang D, Puschhof J, Geurts MH, Yeung A, Hamele C, Smith A, Bankaitis E, Xiang K, Ding S, Nelson D, Delubac D, Rios A, Abi-Hachem R, Jang D, Goldstein BJ, Glass C, Heaton NS, Hsu D, Clevers H, Shen X. Rapid tissue prototyping with micro-organospheres. *Stem Cell Reports*. 2022; 17(9):1959–1975. PMID: 35985334. PMCID: PMC9481922.
 13. Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. *Front Immunol*. 2016; 7:91. PMID: 27014270. PMCID: PMC4789404.
 14. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. *Nat Immunol*. 2003; 4(6):557–564. PMID: 12740575.
 15. Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis e Sousa C. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. *Cell*. 2018; 172(5):1022–1037 e1014. PMID: 29429633. PMCID: PMC5847168.
 16. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Activation of NK cells by CC chemokines. Chemotaxis, Ca²⁺ mobilization, and enzyme release. *J Immunol*. 1996; 156(1):322–327. PMID: 8598480.
 17. Yang M, Chen S, Du J, He J, Wang Y, Li Z, Liu G, Peng W, Zeng X, Li D, Xu P, Guo W, Chang Z, Wang S, Tian Z, Dong Z. NK cell development requires Tsc1-dependent negative regulation of IL-15-triggered mTORC1 activation. *Nat Commun*. 2016; 7:12730. PMID: 27601261. PMCID: PMC5023956.
 18. Segovis CM, Schoon RA, Dick CJ, Nacusi LP, Leibson PJ, Billadeau DD. PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. *J Immunol*. 2009; 182(11):6933–6942. PMID: 19454690. PMCID: PMC2706535.
 19. Wensveen FM, Jelencic V, Polic B. NKG2D: A Master Regulator of Immune Cell Responsiveness. *Front Immunol*. 2018; 9:441. PMID: 29568297. PMCID: PMC5852076.
 20. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. *Immunol Cell Biol*. 2011; 89(2):216–224. PMID: 20567250.

Figures




Figure 1

UMCD6 increases survival and augments killing by human PBMC of a breast cancer line xenotransplanted into immunodeficient mice.

A: Schematic representation of *in vivo* visualization of tumor growth by the IVIS imaging system. **B:** 2×10^6 MDA-MB-231 cells were inoculated s.c. in the abdomen of female SCID/beige mice. Once tumors reached 1 cm, mice were administered 10×10^6 human PBMCs by tail vein (day 0). The next day, mice were injected with 0.1 mg control IgG or UMCD6. **C:** Tumor growth, measured by IVIS, showed a robust decrease in bioluminescence signal in mice treated with UMCD6 compared to IgG and control (not administered PBMCs nor antibodies). The effect of UMCD6 on tumor

volume can be seen from day 7 after UMCD6 administration (** $p < 0.01$) and was maintained until mice were euthanized (** $p < 0.01$). Data represents mean of 4-8 animals \pm SD. **D:** Survival was significantly prolonged in the UMCD6 group compared to the IgG and control groups (** $p < 0.001$).




Figure 2

The effect of UMCD6 is more sustained than pembrolizumab in the killing of MDA-MB-231-derived xenograft tumors by PBMC. **A and B:** We conducted a short-term *in vivo* experiment in which SCID/mice were first inoculated with MDA-MB-231 breast cancer cells, then administered 10×10^6 human PBMCs and antibodies (UMCD6, pembrolizumab or IgG; 100 μ g). Both UMCD6 and pembrolizumab enhanced tumor killing by PBMC at day 8 compared to IgG control ($*p < 0.05$), but only UMCD6 showed

statistical significance at day 11 ($*p < 0.05$). Data represents mean of 4-5 animals \pm SD. **C:** Representative pictures of tumor tissues immunostained for CD56 (human NK cell marker) at day 12 after treatment with UMCD6. **D:** Immunofluorescence of tumor sections stained for the presence of NK cells showed that mice administered UMCD6 had an increased number of tumor-infiltrating NK cells compared to IgG control group (40X). **E:** Characterization of tumor-infiltrating lymphocytes (TILs) by flow cytometry shows that tumor-infiltrating NK cells are found in higher proportions in mice treated with UMCD6. NK cells are more abundant in UMCD6-treated mice (average of 5.8% among TILs) compared with IgG (2.01%) and anti-PD-1 (1.92%). Moreover, tumor-infiltrating NK cells from UMCD6-treated xenografts express higher levels of the activating receptor NKG2D ($*p < 0.05$ vs IgG). **F:** Similarly, NKG2D expression in tumor-infiltrating NKT cells is significantly elevated upon treatment with UMCD6 ($*p < 0.05$ vs IgG), accompanied with an increase in perforin expression (ns).




Figure 3

UMCD6 increases cytotoxicity of tumor-infiltrating lymphocytes (TILs). **A:** TILs from breast cancer MDA-MB-231 xenograft tumors were analyzed by flow cytometry 3 days after treatment with UMCD6 or IgG antibodies. TILs from UMCD6-treated mice had higher levels of NK cells (3.14% \pm 0.6), NKT cells (18.65% \pm 2.25) and CD8+ T cells (16.18% \pm 4.28) compared to TILs from IgG-treated mice: NK cells (2.33% \pm

0.37), NKT cells (14.72% ± 2.74) and CD8+ T cells (13.90% ± 2.33). On the contrary, CD4+ T cells from UMCD6-treated mice were found in lower proportions (57.16% ± 5.79) compared to IgG-treated mice (62.15% ± 6.28). **B:** We found a significant increased frequency of NK cells (**p* < 0.05), specifically CD56 dim cells (**p* < 0.05), in UMCD6-treated mice compared to IgG-treated mice. **C:** CD3+CD56+ NKT cells from UMCD6-treated mice were found to have enhanced perforin expression compared to control-treated mice (**p* < 0.05). **D:** Perforin production was significantly up-regulated in a small portion of CD4 cells (**p* < 0.05) in UMCD6-treated mice.




Figure 4

UMCD6 alters gene expression in human NK cells to enhance cytotoxic function. **A:** RNA-seq data obtained using NK-92 cells stimulated with UMCD6 in a 6-hour culture shows widespread changes in gene expression of 180 genes. **B:** Up-regulation of the activating NK receptors NKG2D (*Klrk1*), DAP10 (*Hcst*) and 2B4 (*CD244*), shown to be involved in the activation of NK cells, was confirmed by RT-PCR. **C:** Schematic representation of the role of UMCD6 in the activation of NK cells. Internalization of CD6 by UMCD6 up-regulates the expression of the activating receptor NKG2D-DAP10 and PI3K pathway. **D:** PI3K and mTOR expression, down-stream pathways of NKG2D-DAP10 signaling complex, were found up-

regulated at protein level in a 72-hour co-culture of NK-92 cells with UMCD6. Data expressed as mean +/- SD and *p<0.05.




Figure 5

UMCD6 enhances NK killing of human breast cancer cells *in vivo*. **A:** Bioluminescence images of breast cancer MDA-MB-231 SCID/beige xenografts infused with 1×10^6 human NK cells and injected with $100 \mu\text{g}$ of antibodies (UMCD6 or IgG) at day 7. Control mice were not administered NK cells or antibodies. **B:** Bioluminescence imaging of MDA-MB-231 mice revealed a decrease in tumor growth in mice receiving NK cells and UMCD6 at day 3 and 8 compared to mice receiving NK cells and IgG control antibody. **C:** Survival rate was significantly increased in the UMCD6 group compared to both the IgG and control groups. UMCD6 vs. IgG, *p = 0.0246; UMCD6 vs. untreated, *p = 0.0389.




Figure 6

UMCD6 enhances killing of patient-derived lung cancer micro-organospheres (MOS). **A:** Lung cancer MOS generated from cancer patient tissues were used in co-cultures with PBMC pre-incubated with UMCD6, nivolumab (anti-PD-1), mouse IgG or human IgG antibodies at 10 $\mu\text{g}/\text{ml}$. UMCD6 induces apoptosis of lung tumor cells in MOS, at least as efficiently as nivolumab, a PD-1 inhibitor in 2 out of 3 samples (501534 and 501252). Tumor cell killing was measured as the number and relative fluorescence of cancer cells in each well expressing Annexin-V (green fluorescence). **B:** UMCD6 showed superiority to mouse and human IgG (after 12 hours; (***) $p < 0.001$) and anti-PD-1 (at 42 hours; ($*$) $p < 0.05$); (data expressed as mean \pm SD; green fluorescence, Annexin-V sensitive with y-axis linear). **C:** Incucyte® images from lung cancer organoids (501252) at day 4 in the presence of antibodies. **D:** T-cell/epithelial cell ratio (T cells/EpCAM ratio) and presence of PDL-1 were measured in each tumor MOS samples.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigures.docx](#)